News | March 24, 2025
Briefs: Alembic Pharmaceuticals and Shelter Pharma
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Previously, Sujatha has held leadership positions at prominent organizations, including Publicis Sapient, Infinite Computer Solutions, and Capgemini
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Subscribe To Our Newsletter & Stay Updated
